Background and objectives Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that is often diagnosed when affected individuals die with respiratory failure. Currently, there are few bibliometrics studies on ALS.
Methods In this study, a comprehensive literature search using the PubMed, WangFang, China National Knowledge Infrastructure, and Chinese Science and Technology Periodical databases was conducted. The Core Collection database for scientific output related to ALS from 1990 to 2022 was also searched. The retrieved dataset was analyzed using.
Results A total of 12,450 articles published since 1990 were retrieved, and 243 articles were included in this study. Thirty-two countries contributed to ALS research, among which Italy had the dominant position with the highest number of publications. In addition, keyword co-occurrence was analyzed. As the three indirect subjects of this article, the sources, affiliations, as well as authors of the study were included in the analysis.
Conclusion In recent years, ALS research has made some progress in terms of elucidating the mechanism of the disease and providing clinical treatment, but the results are concentrated in the United States and European countries. For more complicated research results, critical analysis must be performed.
Acknowledgments
None to declare.
Funding
This work was supported by the 2022 Research and Cultivation Fund of Capital Medical University—An exploration of the “enteric-muscle” axis mechanism of acupuncture intervention in amyotrophic lateral sclerosis (PYZ22034).
Conflict of interest
The authors have no conflict of interests related to this publication.
Author contributions
Manuscript drafting (XDY) and supervising (TQW).
| [1] |
Marin B, Boumédiene F, Logroscino G, Couratier P, Babron MC, Leute-negger AL, et al. Variation in worldwide incidence of amyotrophic lat-eral sclerosis: a meta-analysis. Int J Epidemiol 2017; 46(1):57-74. doi: 10.1093/ije/dyw061,PMID:27185810.
|
| [2] |
Liao Y, He S, Liu D, Gu L, Chen Q, Yang S, et al. The efficacy and safety of Chinese herbal medicine as an add-on therapy for amyotrophic lateral sclerosis: An updated systematic review and meta-analysis of rand-omized controlled trials. Front Neurol 2022;13:988034. doi:10.3389/fneur.2022.988034,PMID:36277914.
|
| [3] |
Zoccolella S, Santamato A, Lamberti P. Current and emerging treat-ments for amyotrophic lateral sclerosis. Neuropsychiatr Dis Treat 2009; 5:577-595. doi:10.2147/ndt.s7788,PMID:19966906.
|
| [4] |
van Eijk RPA, Eijkemans MJC, Nikolakopoulos S, Jansen MD, West-eneng HJ, van Eijk KR, et al. Pharmacogenetic interactions in amyo-trophic lateral sclerosis: a step closer to a cure? Pharmacogenom-ics J 2020; 20(2):220-226. doi:10.1038/s41397-019-0111-3,PMID:31624333.
|
| [5] |
Yun Y, Ha Y. CRISPR/Cas9-Mediated Gene Correction to Understand ALS. Int J Mol Sci 2020; 21(11):3801. doi:10.3390/ijms21113801,PMID:32471232.
|
| [6] |
Barczewska M, Grudniak M, Maksymowicz S, Siwek T, Ołdak T, Jezierska-Woźniak K, et al. Safety of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy. Neural Regen Res 2019; 14(2):313-318. doi:10.4103/1673-5374.243723,PMID:30531015.
|
| [7] |
Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS Genet-ics, Mechanisms, and Therapeutics: Where Are We Now? Front Neuro-sci 2019;13:1310. doi:10.3389/fnins.2019.01310,PMID:31866818.
|
| [8] |
Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, et al. Safety and Effectiveness of Long-term Intravenous Administra-tion of Edaravone for Treatment of Patients with Amyotrophic Lateral Sclerosis. JAMA Neurol 2022; 79(2):121-130. doi:10.1001/jamaneu-rol.2021.4893,PMID:35006266.
|
| [9] |
Oh KW, Noh MY, Kwon MS, Kim HY, Oh SI, Park J, et al. Repeated In-trathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. Ann Neurol 2018; 84(3):361-373. doi:10.1002/ana.25302,PMID:30048006.
|
| [10] |
Schröder S, Wang M, Sima D, Schröder J, Zhu X, Zheng X, et al. Slower progression of amyotrophic lateral sclerosis with external application of a Chinese herbal plaster-The randomized, placebo-controlled triple-blinded ALS-CHEPLA trial. Front Neurol 2022;13:990802. doi:10.3389/fneur.2022.990802,PMID:36324375.
|
| [11] |
Clinical Review Report:Edaravone (Radicava). Indication:For the treatment of amyotrophic lateral sclerosis. CADTH Common Drug Re-views. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019. Available from:
|
| [12] |
Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol 2019; 32(5):771-776. doi:10.1097/WCO.0000000000000730,PMID:31361627.
|
| [13] |
Cui C, Sun J, McKay KA, Ingre C, Fang F. Medication use and risk of amyotrophic lateral sclerosis-a systematic review. BMC Med 2022; 20(1):251. doi:10.1186/s12916-022-02442-w,PMID:35927763.
|
| [14] |
Beswick E, Fawcett T, Hassan Z, Forbes D, Dakin R, Newton J, et al. A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease. J Neurol 2022; 269(12):6254-6268. doi:10.1007/s00415-022-11312-7,PMID:35945397.
|
| [15] |
Pupillo E, Messina P, Logroscino G, Beghi E, SLALOM Group. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol 2014; 75(2):287-297. doi:10.1002/ana.24096,PMID:24382602.
|
| [16] |
Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical re-view. Eur J Neurol 2020; 27(10):1918-1929. doi:10.1111/ene.14393,PMID:32526057.
|
| [17] |
Li H, Pan YG, Wang L. Bibliometrix: Introduction and evaluation of a new R Language bibliometrix software. J Uni Libr Inform Sci 2018; 36(4):93-104.
|
| [18] |
Durieux V, Gevenois PA. Bibliometric indicators: quality measurements of scientific publication. Radiology 2010; 255(2):342-351. doi:10.1148/radiol.09090626,PMID:20413749.
|
| [19] |
Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive sci-ence mapping analysis. J Informetr 2017; 11(4):959-975. doi:10.1016/j.joi.2017.08.007.
|
| [20] |
Man JP, Weinkauf JG, Tsang M, Sin DD. Why do some countries publish more than others? An international comparison of research funding, English proficiency and publication output in highly ranked general medical journals. Eur J Epidemiol 2004; 19(8):811-817. doi:10.1023/b:ejep.0000036571.00320.b8,PMID:15469039.
|
| [21] |
Ray J, Berkwits M, Davidoff F. The fate of manuscripts rejected by a general medical journal. Am J Med 2000;109(2):131-135. doi:10.1016/s0002-9343(00)00450-2, PMID:10967154.
|
| [22] |
Ramírez-Castañeda V. Disadvantages in preparing and publishing scientific papers caused by the dominance of the English language in science: The case of Colombian researchers in biological sciences. PLoS One 2020; 15(9):e0238372. doi:10.1371/journal.pone.0238372,PMID:32936821.
|
| [23] |
Yeung AWK, Tosevska A, Klager E, Eibensteiner F, Laxar D, Stoyanov J, et al. Virtual and Augmented Reality Applications in Medicine: Analy-sis of the Scientific Literature. J Med Internet Res 2021; 23(2):e25499. doi:10.2196/25499,PMID:33565986.
|
| [24] |
Nagai Y. Keywords for study of pathological conditions of neurodegen-erative diseases Rinsho Shinkeigaku 2012; 52(11):874-876. doi:10.5692/clinicalneurol.52.874, PMID:23196448. (in Chinese).
|
| [25] |
Ito D. Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis. Ann Neurol 2022; 91(1):13-20. doi:10.1002/ana.26259,PMID:34704267.
|
| [26] |
Johnson SA, Fang T, De Marchi F, Neel D, Van Weehaeghe D, Berry JD, et al. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. Drugs 2022; 82(13):1367-1388. doi:10.1007/s40265-022-01769-1,PMID:36121612.
|
| [27] |
Rahbaran M, Zekiy AO, Bahramali M, Jahangir M, Mardasi M, Sakhaei D, et al. Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underly-ing mechanisms, current status, and prospects. Cell Mol Biol Lett 2022; 27(1):56. doi:10.1186/s11658-022-00359-z,PMID:35842587.
|
| [28] |
Schmitz-Peiffer H, Aust E, Linse K, Rueger W, Joos M, Löhle M, et al. Motor-Independent Cognitive Testing in Motor Degenerative Dis-eases. J Clin Med 2022; 11(3):814. doi:10.3390/jcm11030814,PMID:35160265.
|
| [29] |
Yang J, Li Y, Liu Q, Li L, Feng A, Wang T, et al. Brief introduction of medi-cal database and data mining technology in big data era. J Evid Based Med 2020; 13(1):57-69. doi:10.1111/jebm.12373,PMID:32086994.
|
| [30] |
Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating re-trieval qualities of Google Scholar, PubMed, and 26 other resources. Res Synth Methods 2020; 11(2):181-217. doi:10.1002/jrsm.1378,PMID:31614060.
|
| [31] |
Ismail II, Saqr M. A Quantitative Synthesis of Eight Decades of Glob-al Multiple Sclerosis Research Using Bibliometrics. Front Neurol 2022;13:845539. doi:10.3389/fneur.2022.845539,PMID:35280299.
|
| [32] |
Chawla S, Shelly S, Phord-Toy R, Khosa F. Need for Speed: Investi-gating Publication Times and Impact Factors of Plastic Surgery Jour-nals. Plast Reconstr Surg Glob Open 2021; 9(10):e3838. doi:10.1097/GOX.0000000000003838,PMID:34616641.
|
| [33] |
Shi G, Zhou J, Huang K, Bi FF. Trends in global amyotrophic lateral sclero-sis research from 2000 to 2022: A bibliometric analysis. Front Neurosci 2022;16:965230. doi:10.3389/fnins.2022.965230,PMID:36033620.
|
| [34] |
Brenner D, Freischmidt A. Update on genetics of amyotrophic lat-eral sclerosis. Curr Opin Neurol 2022; 35(5):672-677. doi:10.1097/WCO.0000000000001093,PMID:35942673.
|
PDF
